title: Native lipoproteins inhibit platelet activation induced by oxidized lipoproteins.
abstract: Copper-catalyzed oxidation of low-density lipoproteins (LDL) (0.8 g protein/l LDL, 20 mumol/l CuSo4, 37 degrees C) resulted in the formation of thiobarbituric reactive substances that was substantially completed at 24 hrs whereas their formation from high-density lipoproteins (HDL) plateaued at only 25% of that amount after 8 hrs. The oxidized lipoproteins induced aggregation and increases in [Ca2+]i in washed platelets, but not in platelet-rich plasma, and these activating effects were not inhibited by aspirin or EGTA but were inhibited by both of the native lipoproteins. These results show that oxidized HDL, like oxidized LDL, have platelet activating ability and suggest that the native lipoproteins may play a crucial role in preventing the oxidized lipoprotein-mediated platelet activation.
authors.affiliation: Department of Laboratory Medicine, Hokkaido University School of Medicine, Sapporo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Takahashi
authors.forename: H
authors.initials: H
authors.lastname: Chiba
authors.forename: K
authors.initials: K
authors.lastname: Matsuno
authors.forename: H
authors.initials: H
authors.lastname: Akita
authors.forename: S P
authors.initials: SP
authors.lastname: Hui
authors.forename: H
authors.initials: H
authors.lastname: Nagasaka
authors.forename: H
authors.initials: H
authors.lastname: Nakamura
authors.forename: K
authors.initials: K
authors.lastname: Kobayashi
authors.forename: N N
authors.initials: NN
authors.lastname: Tandon
authors.forename: G A
authors.initials: GA
authors.lastname: Jamieson
mesh_terms: D001241:Aspirin / Q000494:pharmacology; D002118:Calcium / Q000097:blood; D003300:Copper / Q000494:pharmacology; D019327:Copper Sulfate; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D015227:Lipid Peroxidation; D008074:Lipoproteins / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000494:pharmacology*; D008075:Lipoproteins, HDL / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000494:pharmacology; D008315:Malondialdehyde / Q000097:blood; D010084:Oxidation-Reduction; D015539:Platelet Activation / Q000187:drug effects / Q000502:physiology*; D010974:Platelet Aggregation / Q000187:drug effects / Q000502:physiology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis; D013928:Thromboxane A2 / Q000031:analogs & derivatives / Q000494:pharmacology; D013997:Time Factors
chemical_list: D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D010975:Platelet Aggregation Inhibitors; D017392:Thiobarbituric Acid Reactive Substances; D008315:Malondialdehyde; D013928:Thromboxane A2; D003300:Copper; C049855:ONO 3708; D019327:Copper Sulfate; D001241:Aspirin; D002118:Calcium